Therefore, we first selected exenatide to test the therapeutic effect of tour strategy on MASLD
doi: 10.2174/1574884713666180221121512
The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release
Here's what we'll cover Here's what we'll cover Here's what we'll cover Key takeaways Weight loss injections such as semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound) work by mimicking a hormone that helps curb hunger and increase feelings of fullness after eating
During the initiation phase, follow-up every 2 to 4 weeks can help manage side effects and optimize dosing
But here again, the causality isnt settled